Company: WHWK
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001628280-25-020311
Chunk: 34

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 34
---
 |         |     |               |       — |        |     |           |     — |       |     |            | — |            |     |                                                             |     | 30,000 |     |                                                                      |         | 94,650 |
|                             |     | 3/1/2023      |     |             |  44,778 |         |     |               |  57,572 |        |     |           | 10.93 |       |     |            |   | 3/1/2033   |     |                                                             |     |        |     |                                                                      |         |        |
|                             |     | 4/1/2022      |     |             |  44,866 |         |     |               |  22,434 |        |     |           | 17.24 |       |     |            |   | 4/1/2032   |     |                                                             |     |        |     |                                                                      |         |        |
|                             |     | 10/21/2021    |     |             | 146,458 |         |     |               |  38,542 |        |     |           | 26.85 |       |     |            |   | 10/21/2031 |     |                                                             |     |        |     |                                                                      |         |        |

(1) Unless otherwise noted, each option vests 25% on the first anniversary of the grant date, then vests in 36 equal monthly installments thereafter, such that the option is vested on the fourth anniversary of the grant date, subject to the holder continuing to provide services to the Company through each applicable vesting date.

(2) Calculated by multiplying the number of unvested shares by $3.155, the closing price per share of our common stock on Nasdaq on Dece mber 31, 2024, the last trading day of 2024.

(3) Each option was granted in respect of amounts payable to such named executive officers under our 2023 bonus plan and was fully vested at grant.

(4) 25% of such restricted stock units will vest on each anniversary of the grant date, subject to the holder continuing to provide services to the Company through each applicable vesting date.

(5) 100% of such restricted stock units vested on October 2, 2024.

<div align='center'>21</div>

#### Employment Agreements